DeutschNewstral
Article
bizjournals.com on 2015-08-20 22:05
Seattle biotech Adaptive lives up to its name, pivots toward drug development
Related news
Seattle biotech Adaptive buys San Francisco firmseattletimes.com
Adaptive Biotech seeks $230 million in IPOSeattle Times- Adaptive Biotech hires CFO who helped Zilllow go publicseattletimes.com
- Former Zillow CFO heads to Seattle biotechbizjournals.com
- Black Lives Matter protest in Seattle discourages hate toward police: ‘We need you’seattletimes.com
- Seattle biotech Kineta lands $4M contract to develop immunotherapy for infectious diseasebizjournals.com
- Here's why one biotech, courted by San Diego, decided to stay in Seattlebizjournals.com
- This Seattle venture firm just raised $262M to focus on biotechbizjournals.com
- Boulder biotech acquires Seattle companybizjournals.com
- Seattle biotech Adaptive Biotechnologies to partner with GenentechSeattle Times
- Biotech led venture-backed IPOs nationally in 2014 including Juno Therapeutics, 3 other Seattle biotechsbizjournals.com
- Seattle brothers expand billion-dollar biotech company’s focus to include COVIDSeattle Times
- Seattle biotech faces tough decision about its next CEO in midst of proxy battlebizjournals.com
- One year, nearly $400M and a plan to improve drug testing: This Seattle biotech is roaringbizjournals.com
- Seattle biotech inks deal worth up to $535M with Kite Pharmabizjournals.com
- Shares of Adaptive Biotechnologies leap after Seattle firm’s IPOSeattle Times
- Adaptive Biotechnologies signs lease for new Seattle headquartersbizjournals.com
- Seattle biotech outpaces Washington's public companiesbizjournals.com
- Seattle biotech expands portfolio with Boston acquisitionbizjournals.com
- Seattle biotech Faraday Pharmaceuticals names new CEObizjournals.com